Abstract
Background: Despite the progressive improvement in current treatment, one fourth of children with acute lymphoblastic leukemia (ALL) still relapse and endure dismal prognosis. In the present study, we introduce more evidence of the antiproliferative effects of 3-[(dodecylthiocarbonyl)-methyl]- glutarimide (DTCM-g), a novel synthetic derivative of 9-methylstreptimidone, on four childhood ALL derived cell lines.
Methods: REH, NALM-6, MOLT4 and Jurkat cell lines were treated with varied doses of DTCM-g (2.5 to 20ug/mL) and analyzed in terms of growth (Resazurin reduction), apoptosis (caspase-activation) and cell cycle dynamics. The impact on drug interactions in simultaneous treatments with vincristine, methotrexate and 6-mercaptopurine was also investigated. Results: Our results showed statistically significant reductions in growth in dose- and time-dependent manner, as compared with untreated control cells. In parallel, DTCM-g treatment mediated a significant increase in apoptosis and arrest at the G1 stage of the cell cycle. Alternatively, DTCM-g failed to potentiate the cytotoxicity of the commonly used drugs in 3 of the ALL cell lines studied. Conclusion: Together the data reinforce the anticancer potential of DTCM-g although its applicability in polychemotherapeutic treatments deserves further investigation.Keywords: DTCM-g, leukemia, cell lines, drugs, chemotherapy, growth.
Current Bioactive Compounds
Title:DTCM-Glutarimide Hinders Growth of Childhood Leukemia Cells but Fails to Improve the Efficacy of Commonly Used Chemotherapeutic Agents
Volume: 13 Issue: 1
Author(s): Julia A. Pezuk, Gabriela M. Roberto, Kazuo Umezawa and Maria Sol Brassesco
Affiliation:
Keywords: DTCM-g, leukemia, cell lines, drugs, chemotherapy, growth.
Abstract: Background: Despite the progressive improvement in current treatment, one fourth of children with acute lymphoblastic leukemia (ALL) still relapse and endure dismal prognosis. In the present study, we introduce more evidence of the antiproliferative effects of 3-[(dodecylthiocarbonyl)-methyl]- glutarimide (DTCM-g), a novel synthetic derivative of 9-methylstreptimidone, on four childhood ALL derived cell lines.
Methods: REH, NALM-6, MOLT4 and Jurkat cell lines were treated with varied doses of DTCM-g (2.5 to 20ug/mL) and analyzed in terms of growth (Resazurin reduction), apoptosis (caspase-activation) and cell cycle dynamics. The impact on drug interactions in simultaneous treatments with vincristine, methotrexate and 6-mercaptopurine was also investigated. Results: Our results showed statistically significant reductions in growth in dose- and time-dependent manner, as compared with untreated control cells. In parallel, DTCM-g treatment mediated a significant increase in apoptosis and arrest at the G1 stage of the cell cycle. Alternatively, DTCM-g failed to potentiate the cytotoxicity of the commonly used drugs in 3 of the ALL cell lines studied. Conclusion: Together the data reinforce the anticancer potential of DTCM-g although its applicability in polychemotherapeutic treatments deserves further investigation.Export Options
About this article
Cite this article as:
Pezuk A. Julia, Roberto M. Gabriela, Umezawa Kazuo and Brassesco Sol Maria, DTCM-Glutarimide Hinders Growth of Childhood Leukemia Cells but Fails to Improve the Efficacy of Commonly Used Chemotherapeutic Agents, Current Bioactive Compounds 2017; 13 (1) . https://dx.doi.org/10.2174/1573407212666160622092352
| DOI https://dx.doi.org/10.2174/1573407212666160622092352 |
Print ISSN 1573-4072 |
| Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
Call for Papers in Thematic Issues
“Waste Fruit Peels and Plant Parts: Innovative Green Approach for Bioactives and Nanoparticle Synthesis”
The escalating demand for eco-friendly and sustainable nanotechnology has led to the exploration of innovative green approaches for nanoparticle synthesis. Among these, the utilization of waste fruit peels as bio-reductants and stabilizers has emerged as a promising, cost-effective, and environmentally benign strategy. Fruit peels, often discarded as waste, and are ...read more
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current and Emerging Strategies in Bladder Cancer
Anti-Cancer Agents in Medicinal Chemistry Resilient Brain Aging: Characterization of Discordance between Alzheimer’s Disease Pathology and Cognition
Current Alzheimer Research Uric acid and Metabolic Syndrome: What is the Relationship?
Current Rheumatology Reviews Vitamin D Insufficiency and Diabetes Risks
Current Drug Targets New Purine Nucleoside Analogs for Acute Lymphoblastic Leukemia
Clinical Cancer Drugs Paraneoplastic Neurological Syndromes - Diagnosis and Management
Current Pharmaceutical Design Role of Drug Metabolism in the Cytotoxicity and Clinical Efficacy of Anthracyclines
Current Drug Metabolism Editorial (Hot Topic: Pharmacological Developments in Assisted Reproduction)
Current Drug Targets The Spleen Tyrosine Kinase (Syk) in Human Disease, Implications for Design of Tyrosine Kinase Inhibitor Based Therapy
Current Pharmaceutical Design Towards a “Metabolic” Subtype of Major Depressive Disorder: Shared Pathophysiological Mechanisms May Contribute to Cognitive Dysfunction
CNS & Neurological Disorders - Drug Targets Utility of Assessing Thiopurine S-methyltransferase Polymorphisms Before Azathioprine Therapy
Current Drug Metabolism Clinical and Pre-clinical Applications of the Transcendental Meditation Program® in the Prevention and Treatment of Essential Hypertension and Cardiovascular Disease in Youth and Adults
Current Hypertension Reviews NGS Technologies as a Turning Point in Rare Disease Research , Diagnosis and Treatment
Current Medicinal Chemistry Flavonoids in Atherosclerosis: An Overview of Their Mechanisms of Action
Current Medicinal Chemistry The Posttranslational Phase of Gene Expression: New Possibilities in Molecular Diagnosis
Current Molecular Medicine Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment
Current Cardiology Reviews Busulphan in Blood and Marrow Transplantation: Dose, Route, Frequency and Role of Therapeutic Drug Monitoring
Current Clinical Pharmacology Is there a Rational Approach for Increasing Drug Specificity? Considerations on CNS Target Choice and Validation
Recent Patents on CNS Drug Discovery (Discontinued) Possible Exploitation of Non-Neuronal and Non-Chemical Synaptic Signalling Pathways in Epilepsy Therapy
Current Signal Transduction Therapy Targeting Focal Adhesion Kinase in Neuroblastoma
Anti-Cancer Agents in Medicinal Chemistry





